References

Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20(5):620–34.

Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;8:17.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–38.

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/ independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–37.

Iwata H. Clinical development of CDK4/6 inhibitor for breast cancer. Breast Cancer. 2018;25(4):402–6.

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 Inhibitors: The mechanism of action may not be as simple as once thought. Cancer Cell. 2018; [Epub ahead of print].

Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer. 2017;3(1):39–55.

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, et al. ATRX is a regulator of therapy induced senescence in human cells. Nat Commun. 2017;8(1):386.

Kovatcheva M, Liu DD, Dickson MA, Klein ME, O'Connor R, Wilder FO, et al. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget. 2015;6(10):8226–43.

Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2013;137(2):483–92.

Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.

Murphy CG, Dickler MN. The role of CDK4/6 inhibition in breast cancer. Oncologist. 2015;20(5):483–90.

NCT02536742. Palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer (PYTHIA). Available at https://clinicaltrials.gov/ct2/show/NCT02536742?term=NCT02536742&rank=1. Accessed June 2018.

NCT03195192. Utilizing multiomic advanced diagnostics to identify CDK 4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer. Available at https://clinicaltrials.gov/ct2/show/NCT03195192?term=NCT03195192&rank=1. Accessed June 2018.

Shah M, Nunes MR, Stearns V. CDK4/6 Inhibitors: Game changers in the management of hormone receptor–positive advanced breast cancer? Oncology (Williston Park). 2018;32(5):216–22.

Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23(13):3251–62.
Login/ Register Maximise Minimise